Related Experiment Videos
Rifampim-combined chemotherapy in coal worker's pneumoconio-tuberculosis
The American Review of Respiratory Disease
|February 1, 1977
Summary
Rifampin-combined chemotherapy effectively treated coal miners with pneumoconiosis and tuberculosis, achieving high sputum conversion rates. This treatment largely overcomes challenges posed by coexisting conditions, with minimal side effects.
Area of Science:
- Pulmonary Medicine
- Infectious Diseases
- Occupational Health
Background:
- Pneumoconiosis, a lung disease from coal dust, often coexists with tuberculosis.
- Managing tuberculosis in patients with pneumoconiosis presents unique challenges.
Purpose of the Study:
- To evaluate the efficacy of rifampin-combined chemotherapy in coal miners with pneumoconiosis-tuberculosis.
- To assess bacteriologic conversion rates and treatment outcomes in this patient population.
Main Methods:
- Retrospective study of 59 coal miners with pneumoconiosis-tuberculosis.
- Treatment involved rifampin combined with other drugs, with some patients receiving retreatment.
- Follow-up ranged from 24 to 78 months.
Main Results:
- 90% of patients achieved sputum conversion.
- Initial treatment group had 100% conversion at 5 months; retreatment group had 84.4% conversion.
- Rifampin-based regimens showed results comparable to advanced tuberculosis without pneumoconiosis.
Conclusions:
- Rifampin-combined chemotherapy is effective in treating tuberculosis in coal miners with pneumoconiosis.
- The treatment largely negates the complications of coexisting tuberculosis and pneumoconiosis.
- Rifampin had minimal side effects; mortality was primarily due to cardiorespiratory insufficiency.